Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

barusiban

Known as: C4.6,S1-Cyclo(N-(3-sulfanylpropanoyl)-D-tryptophyl-L-isoleucyl-L-alloisoleucyl-L-asparaginyl-L-2-aminobutanoyl-N-methyl-L-ornithinol) 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract The use of drugs in pregnancy always raises concerns regarding potential fetal exposure and possible adverse effects… Expand
2014
2014
We compared the neonatal and infant outcomes at one year (Bayley mental and psychomotor development index, and physical growth… Expand
2013
2013
The invention relates to the technical field of medicine and discloses a barusiban injection and a preparation method thereof… Expand
2009
2009
OBJECTIVE The objective of the study was to compare barusiban with placebo in threatened preterm labor. STUDY DESIGN This was a… Expand
2007
2007
BackgroundPreterm labour (PTL) is a major cause of neonatal mortality and morbidity, and oxytocin (OT) antagonists are potential… Expand
  • table 1
2007
2007
The oxytocin receptor antagonist barusiban, currently being developed for treatment of preterm labour, was investigated in… Expand
2006
2006
Abstract Preterm labor (PTL) affects up to 25% of human pregnancies in developing countries, but there are few therapeutic… Expand
2005
2005
Preterm labor (PTL) represents a significant unmet clinical need that affects up to 20% of all pregnancies and is a leading cause… Expand
2005
2005
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in… Expand
Highly Cited
2004
Highly Cited
2004
Background: A synthetic oxytocin analogue, barusiban, was shown to potently inhibit oxytocininduced activity of myometrium from… Expand
  • figure 1